Analytical Method Development

E1.1  What Arc A already covers, applied here directly

Practice Every parameter from Arc A3 — specificity, accuracy, precision, linearity, range, robustness, LOD/LOQ — applies to assay and related-substances methods without modification. The validate-or-verify distinction from Arc A2 applies the same way: a compendial assay run unmodified is a ⟨1226⟩ verification; a new or modified one is a ⟨1225⟩ validation. Nothing about assay or RS testing exempts it from that framework — if anything, these are the test types the framework was originally built around.

Practice One requirement matters more here than almost anywhere else in this course: assay and related-substances methods intended to support stability studies have to be stability-indicating — capable of detecting a change in the drug substance or product over time, distinguishing the intact molecule from its degradation products, without interference from excipients or other formulation components. That single requirement is what this module's worked example is built around.

E1.2  The Soleo case study, already told

Arc A4 already covered this course's clearest example of an assay method nobody was actually controlling: Soleo's biotin assay, where the HPLC flow rate and injection volume recorded in the analyst's notebook (1 mL/min, 10 µL) didn't match the values in the official HPLC report (0.8 mL/min, 5 µL) for the same sample. That finding does not need retelling here — it already carries this arc's weight as a worked assay-method case study, and Arc A4 is where to find the full citation and quote.

E1.3  A worked example specific to assay/RS: mass balance as a specificity check

Requirement A common way to demonstrate that an assay/RS method is genuinely stability-indicating — genuinely specific, in Arc A3's terms — is a mass balance check after forced degradation: add up the percentage of intact drug (assay) and the percentage of quantified degradation products, and confirm the total is close to 100% of the starting material. If it isn't, the method is missing something.

Figure E1.1

Both scenarios in the figure start from the identical true situation: forced degradation (here, acid stress) has reduced the assay from an initial 100.2% to 92.4%. A fully stability-indicating method resolves and quantifies 7.1% worth of degradation products, giving a mass balance of 92.4% + 7.1% = 99.5% — comfortably inside a 98–102% acceptance convention. A method with a real specificity gap — a degradation product that co-elutes with something else, or was never included in the forced- degradation challenge in the first place — only accounts for 3.0% of the missing material, giving a mass balance of just 95.4%.

Practice The important part: nothing about the underlying chemistry differs between the two scenarios — the same amount of drug degraded either way. The gap in the second case is entirely a property of the method, not the sample. That is exactly what a specificity failure looks like in practice, and it is exactly why mass balance is one of the standard ways ICH-aligned method development confirms a method is genuinely stability-indicating before it gets used to support real stability data.